Eine Studie zur Untersuchung der Sicherheit, Pharmakokinetik und vorläufigen Wirksamkeit der IDE574-Therapie bei erwachsenen Teilnehmern mit fortgeschrittenen soliden Tumoren
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: IDEAYA Clinical Trials
- Telefonnummer: +1-855-433-224
- E-Mail: IDEAYAClinicalTrials@ideayabio.com
Studienorte
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgia, 6000
- Rekrutierung
- High Technology Hospital MedCenter Ltd
-
Hauptermittler:
- Tamta Makharadze, MD
-
Kontakt:
- Mamuka Sikharulidze
- Telefonnummer: +995 568 999 559
- E-Mail: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgia, 114
- Rekrutierung
- Pineo Medical Ecosystem
-
Kontakt:
- Nino Kekenadze
- Telefonnummer: +995 593 660 940
- E-Mail: Nkekenadze@pineo.ge
-
Hauptermittler:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgia, 112
- Aktiv, nicht rekrutierend
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgia, 144
- Aktiv, nicht rekrutierend
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 186
- Aktiv, nicht rekrutierend
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, Vereinigte Staaten, 90404-2095
- Aktiv, nicht rekrutierend
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510-3206
- Rekrutierung
- Yale School of Medicine - Cedar Street
-
Hauptermittler:
- Patricia LoRusso, MD
-
Kontakt:
- Karen Seely
- Telefonnummer: 203-314-3303
- E-Mail: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Vereinigte Staaten, 33322
- Rekrutierung
- Florida Clinical Trials Group
-
Hauptermittler:
- Harshad Amin, MD
-
Kontakt:
- Sandra Perez
- Telefonnummer: 772-297-3057
- E-Mail: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322-1013
- Rekrutierung
- Winship Cancer Institute, Emory University
-
Hauptermittler:
- Shipra Gandhi, MD
-
Kontakt:
- Alejandra Bono
- Telefonnummer: 404-778-0954
- E-Mail: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110-1010
- Rekrutierung
- Washington University - Siteman Cancer Center
-
Hauptermittler:
- Faisal Fa'ak, MD
-
Kontakt:
- Pamela Coe
- Telefonnummer: 314-747-7569
- E-Mail: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Vereinigte Staaten, 08816
- Rekrutierung
- START Astera, LLC
-
Hauptermittler:
- Bruno Fang, MD
-
Kontakt:
- Bruno S Fang
- Telefonnummer: 732-426-4750
- E-Mail: info@startresearch.com
-
-
New York
-
Lake Success, New York, Vereinigte Staaten, 11042
- Rekrutierung
- START New York Long Island, LLC
-
Hauptermittler:
- Geraldine O'Sullivan Coyne, MD
-
Kontakt:
- Geraldine O'Sullivan Coyne
- Telefonnummer: 363-207-5160
- E-Mail: g.osullivancoyne@startresearch.com
-
New York, New York, Vereinigte Staaten, 10032-3729
- Aktiv, nicht rekrutierend
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI Oncology Partners - PPDS
-
Hauptermittler:
- Sarah Premji, MD
-
Kontakt:
- Connor Frost
- Telefonnummer: 615-478-3475
- E-Mail: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78758
- Rekrutierung
- NEXT Texas LLC - Austin
-
Hauptermittler:
- Sheena Sahota, MD
-
Kontakt:
- Heather Watson
- Telefonnummer: 737-610-5202
- E-Mail: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Vereinigte Staaten, 75039
- Rekrutierung
- NEXT Texas LLC - Dallas
-
Hauptermittler:
- Faran Polani, MD
-
Kontakt:
- Carmen Gonzalez
- Telefonnummer: 210-580-9479
- E-Mail: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- START Dallas Fort Worth, LLC
-
Hauptermittler:
- Henry Xiong, MD
-
Kontakt:
- Henry Xiong
- Telefonnummer: 682-350-3010
- E-Mail: info@startresearch.com
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- Rekrutierung
- MD Anderson Cancer Center
-
Hauptermittler:
- Timothy Yap, MD
-
Kontakt:
- Desirae Dufner
- Telefonnummer: 713-524-3434
- E-Mail: DDufner@mdanderson.org
-
Houston, Texas, Vereinigte Staaten, 77054
- Rekrutierung
- NEXT Texas LLC - Houston
-
Hauptermittler:
- Jennifer Segar, MD
-
Kontakt:
- Carmen Gonzalez
- Telefonnummer: 210-580-9479
- E-Mail: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- NEXT Texas LLC - San Antonio
-
Hauptermittler:
- David Sommerhalder, MD
-
Kontakt:
- April Guerra
- Telefonnummer: 210-580-9500
- E-Mail: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Start San Antonio, LLC
-
Hauptermittler:
- Amita Patnaik, MD
-
Kontakt:
- Hector Navarro
- Telefonnummer: 210-593-5700
- E-Mail: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Vereinigte Staaten, 84119
- Rekrutierung
- START Mountain Region, LLC
-
Hauptermittler:
- William McKean, MD
-
Kontakt:
- William B McKean
- Telefonnummer: 1 (801) 907-4750
- E-Mail: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- NEXT Virginia
-
Hauptermittler:
- Mohamad Salkeni, MD
-
Kontakt:
- Maybelle De La Rosa
- Telefonnummer: 703-783-4518
- E-Mail: nxtvir_coordinators@nextoncology.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Experimental: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Experimental: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Zeitfenster: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Zeitfenster: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Zeitfenster: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Zeitfenster: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Zeitfenster: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Zeitfenster: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Zeitfenster: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Zeitfenster: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Zeitfenster: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Zeitfenster: total study duration
|
total study duration
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IDE574-001
- 178299 (Andere Kennung: Regulatory Agency Identifier Number (s))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .